http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-13T11:26:02.404Z

http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

amantadine hydrochloride capsules usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus amantadine hydrochloride capsules usp are also indicated in the treatment of parkinsonism and drug induced extrapyramidal reactions influenza a prophylaxis amantadine hydrochloride capsules usp are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection because amantadine hydrochloride does not completely prevent the host immune response to influenza a infection individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses following vaccination during an influenza a outbreak amantadine hydrochloride capsules usp prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response influenza a treatment amantadine hydrochloride capsules usp are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a virus strains especially when administered early in the course of illness there are no well controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules usp will avoid the development of influenza a virus pneumonitis or other complications in high risk patients there is no clinical evidence indicating that amantadine hydrochloride capsules usp are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules usp amantadine hydrochloride capsules usp is not a substitute for early vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules usp parkinson s disease syndrome amantadine hydrochloride capsules usp are indicated in the treatment of idiopathic parkinson s disease paralysis agitans postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication it is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis in the treatment of parkinson s disease amantadine hydrochloride capsules usp are less effective than levodopa 3 3 4 dihydroxyphenyl l alanine and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established drug induced extrapyramidal reactions amantadine hydrochloride capsules usp are indicated in the treatment of drug induced extrapyramidal reactions although anticholinergic type side effects have been noted with amantadine hydrochloride capsules usp when used in patients with drug induced extrapyramidal reactions there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs

Leoni Bücken

2021-06-13T11:26:02.404Z

http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_14330 DOID_14330

Leoni Bücken

2021-06-13T11:26:02.404Z

http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-13T11:26:02.404Z

http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00915 drugbank:DB00915

Leoni Bücken

2021-06-13T11:26:02.404Z

http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-13T11:26:02.404Z

http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-13T11:26:02.404Z

http://purl.org/np/RAIp4oHPyk... RAIp4oHPyk

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-13T11:26:02.404Z